A cornea 3D printed at India’s L V Prasad Eye Institute (LVPEI), Indian Institute of Technology (IIT) Hyderabad and Centre for Cellular and Molecular Biology has been successfully animal tested for the first time.
Prellis Biologics, a biotherapeutics company utilizing its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro, has appointed Michael Nohaile, PhD as its new CEO, and has raised a $35 million Series C funding round, co-led by Celesta Capital and Avidity Partners with participation from Khosla Ventures, SOSV, True Ventures, and Lucas Venture Group. Dr. Michael Nohaile joins the company from Generate Biomedicines and succeeds Prellis Biologics founder Dr. Melanie Matheu, who will assume the role of Chief Technology Officer and retain a Board seat.
BellaSeno GmbH, an ISO 13485-certified MedTech company developing resorbable chest and breast implant scaffolds using additive manufacturing technologies, began two clinical trials of its products in Australia, which are sponsored by its Australian subsidiary BellaSeno Pty. Already, recruiting has started in Brisbane, Australia.
Stryker, one of the world’s leading medical technology companies, has opened its high-tech 3D printing facility at Anngrove, Cork – marked by a visit from Taoiseach Micheál Martin TD, the IDA, and other local guests. The new 156,000-square-foot development creates capacity for 600 high-tech jobs in the future, and will help further Stryker’s leadership in med-tech additive manufacturing. Stryker has made significant investments in Anngrove to establish itself as a world leader in this technology, and will continue to invest for growth.
Surgeons in Europe now have access to MyBone, a patient-specific 3D printed bone, to treat patients with severe facial deformations. This 3D printed bone is made of hydroxyapatite, a calcium phosphate that is the main mineral component of natural bone. MyBone is 3D printed with a unique porous structure by Cerhum, a medical device company in Liège, Belgium.